ClinicalTrials.Veeva

Menu

PDS*Plus and Wound Infections After Laparotomy (PDS*plus)

U

University Hospital, Saarland

Status

Completed

Conditions

Incisional Hernia
Wound Infection

Treatments

Device: PDS plus
Device: PDS II

Study type

Interventional

Funder types

Other

Identifiers

NCT00998907
09/2009

Details and patient eligibility

About

The aim of this study is to ascertain if the use of PDS plus® reduces the number of wound infections and incisional hernia after midline and transverse laparotomy comparing to polyglactin suture.

Full description

All patients are treated using clinical pathways (CP) to standardise surgical procedures in our high volume centre. Part of the clinical process management was the standardisation of wound incision and abdominal wall closure.

Wound closure is achieved using continuous absorbable loop suture. The suture length to incision length ratio is at least 4:1. The running sutures are 1 cm apart and at least 1.5 cm from the wound edge. In the first time period , the CP step for fascia closure foresees a triclosan-coated PDS 910 loop suture (PDS plus®, Ethicon GmbH, Norderstedt, Germany). In the second time period the CP step will be altered to the use of PDS loop suture (PDS II®, Ethicon GmbH, Norderstedt, Germany). The CP- step is changed every 100 patients to cluster-randomize the patients. The primary outcome is the number of wound infections. Together with this the number of incisional hernia will be recorded. Patients demographic and disease as well as procedure related data are collected in a clinical information system (ISHmed on SAP platform, GSD, Berlin, Germany) prospectively. Risk factors for poor wound healing, such as operation time, patients age, sex, body mass index, blood loss, peritonitis, antibiotics, and performance level classified according to the American Society of Anesthesiologists (ASA), are collected prospectively to compare the two groups.

Enrollment

1,042 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • surgical pathologies accessed via midline or transverse abdominal incision
  • primary fascial closure

Exclusion criteria

  • pregnancy
  • age under 18 years
  • open abdominal treatment
  • known hypersensitivity against PDS/Triclosan

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Single Group Assignment

Masking

None (Open label)

1,042 participants in 2 patient groups

PDS II
Active Comparator group
Description:
PDS II® loop suture is used for abdominal wall closure
Treatment:
Device: PDS II
PDS plus
Experimental group
Description:
antibacterial coated "PDS plus" is used for abdominal wall closure
Treatment:
Device: PDS plus

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems